| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/17/2002 | EP1196595A2 Methods of inducing cell death |
| 04/17/2002 | EP1196587A2 Antigenic meningococcal peptides |
| 04/17/2002 | EP1196584A1 Tetanus toxin polypeptides |
| 04/17/2002 | EP1196579A2 Tryptase inhibitor |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196576A2 Secreted polypeptides and corresponding polynucleotides |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196571A1 Orbit and homologues thereof |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/17/2002 | EP1196564A2 Atherosclerosis-associated genes |
| 04/17/2002 | EP1196562A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196450A1 Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis |
| 04/17/2002 | EP1196448A2 Homomeric and heteromeric ampa receptors |
| 04/17/2002 | EP1196446A1 Protamine-free insoluble acylated insulin compositions |
| 04/17/2002 | EP1196445A1 Insulin crystals for pulmonary administration |
| 04/17/2002 | EP1196444A1 Peptides that lower blood glucose levels |
| 04/17/2002 | EP1196443A2 Erythropoietin conjugates with polyethylenglycol |
| 04/17/2002 | EP1196442A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196439A2 Compounds exhibiting an antibiotic activity |
| 04/17/2002 | EP1196438A1 A ligand of the protein "beacon" |
| 04/17/2002 | EP1196436A2 Peptide boronic acid inhibitors of hepatitis c virus protease |
| 04/17/2002 | EP1196435A1 Recombinant adenovirus |
| 04/17/2002 | EP1196434A2 Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes |
| 04/17/2002 | EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 04/17/2002 | EP1196432A2 FVIIa ANTAGONISTS |
| 04/17/2002 | EP1196431A1 A substantially crystalline form of melagatran |
| 04/17/2002 | EP1196430A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 04/17/2002 | EP1196414A1 Prodrugs of carbamate inhibitors of impdh |
| 04/17/2002 | EP1196400A1 Amino-alkyl derivatives |
| 04/17/2002 | EP1196395A1 Cyclized amino acid derivatives |
| 04/17/2002 | EP1196389A1 N-heterocyclic derivatives with neuronal activity |
| 04/17/2002 | EP1196387A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196386A2 N-substituted glycine derivatives |
| 04/17/2002 | EP1196196A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 04/17/2002 | EP1196193A2 Interleukin-1 muteins useful as vaccine adjuvants |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196190A1 Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases |
| 04/17/2002 | EP1196189A2 Multiple agent diabetes therapy |
| 04/17/2002 | EP1196188A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196187A1 Keratinocyte growth factor-2 formulations |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196184A1 Compositions and methods for treatment of sexual dysfunction |
| 04/17/2002 | EP1196157A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 04/17/2002 | EP1196154A2 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 04/17/2002 | EP1196149A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 04/17/2002 | EP1196148A1 Process for microencapsulation of water soluble substances |
| 04/17/2002 | EP1196128A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 04/17/2002 | EP1196041A2 Methods and means for producing improved dairy products |
| 04/17/2002 | EP1196030A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 04/17/2002 | EP1196027A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 04/17/2002 | EP1121145B1 Insulin preparations for pulmonary delivery containing menthol |
| 04/17/2002 | EP1028730B1 Compositions of lipid lowering agents |
| 04/17/2002 | EP1007561B1 Novel conjugates of opioids and endogenous carriers |
| 04/17/2002 | EP0901378B1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid |
| 04/17/2002 | EP0886652B1 Pulmonary surfactant peptide solubilization process |
| 04/17/2002 | EP0876152B1 Novel administration of thrombopoietin |
| 04/17/2002 | EP0853890B1 Lactose-containing food composition for infants |
| 04/17/2002 | EP0852627A4 Cell death protein |
| 04/17/2002 | EP0851762B1 Pharmaceutical combination preparations containing erythropoietin and iron preparations |
| 04/17/2002 | EP0831902A4 Muscle trophic factor |
| 04/17/2002 | EP0794790B1 Localized delivery of factors enhancing survival of transplanted cells |
| 04/17/2002 | EP0793506B1 Cellular and serum protein anchors and conjugates |
| 04/17/2002 | EP0749305B1 Process for making avermectin/zein compositions |
| 04/17/2002 | EP0742722B1 Method for increasing bioavailability of oral pharmaceutical compositions |
| 04/17/2002 | EP0707485B1 Anti-cholesterolemic egg, vaccine and method for production, and use |
| 04/17/2002 | EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids |
| 04/17/2002 | EP0623146B1 Compositions and methods for inhibiting beta-protein function |
| 04/17/2002 | EP0607278B1 Method for enhancing gut absorption |
| 04/17/2002 | EP0500785B1 A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| 04/17/2002 | EP0359783B2 Treatment of autoimmune diseases by oral administration of autoantigens |
| 04/17/2002 | CN1345376A Protease, gene therefor and use thereof |
| 04/17/2002 | CN1345375A Streptococcus pneumoniae antigens |
| 04/17/2002 | CN1345374A HER-2/neu fusion proteins |
| 04/17/2002 | CN1345336A Antibody and chemokine constructs and their use for treating autoimmune diseases |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345333A Echinocandin/carbohydrate complexes |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345251A Methods and compositions for healing and repair of articular cartilage |
| 04/17/2002 | CN1345247A Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas |
| 04/17/2002 | CN1345246A Compositions and method for prevention or treatment of cancer and bone loss associated with cancer |
| 04/17/2002 | CN1345245A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/17/2002 | CN1345242A Method for treatment of leukaemia |
| 04/17/2002 | CN1345232A Hydrogel particle formulations |
| 04/17/2002 | CN1345230A Processes for making pharmaceutical oral ECB formulations and compositions |
| 04/17/2002 | CN1345229A Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
| 04/17/2002 | CN1345224A Composition for cosmetic and dermatological skin care |
| 04/17/2002 | CN1344800A New polypeptide human phosphoglycerol diesterase 31.56 and polynucleotides encoding this polypeptide |
| 04/17/2002 | CN1344798A New polypeptide human dioxygenase 10.12 and polynucleotides encoding this polypeptide |
| 04/17/2002 | CN1344755A Prep. of degradable polymer, pharmaceutical composition containing the same and its use |
| 04/17/2002 | CN1344745A Martentoxin as one great-conductance calcium-activating potassium channel blocker and its prepn and use |